T3D0315

316 T3D0315

Nitarsone

Nitarsone is an exogenous organic compound with the formula C6H6AsNO5 and an average molecular weight of 247.04 g/mol. It exists as a solid at room temperature. Nitarsone belongs to the nitrobenzenes, a subclass of benzene and substituted derivatives within the organic compounds. It is used as an agrochemical and an antiprotozoal drug. One recorded source of this compound is household cleaning and consumer products, specifically non-electric simulated smoking devices. The compound interacts with 32 recorded protein targets. Arsenic binds to hemoglobin (HBA1 and HBB), the estrogen receptor (ESR1), the glucocorticoid receptor (NR3C1), and haptoglobin. It also binds to various forms of actin, including alpha skeletal muscle (ACTA1), aortic smooth muscle (ACTA2), cytoplasmic 1 (ACTB), and cytoplasmic 2 (ACTG1). Binding to glutathione reductase, mitochondrial (GSR) results in the inhibition of essential biochemical reactions, alteration of cellular redox status, and eventual cytotoxicity. Arsenic binding of XPA is believed to induce carcinogenesis by affecting DNA repair. Furthermore, arsenic disrupts ATP production through several mechanisms. Within the citric acid cycle, it inhibits pyruvate dehydrogenase—specifically PDHA1, PDHA2, PDHB, and DLAT—and uncouples oxidative phosphorylation by competing with phosphate. This process inhibits ATP synthesis, mitochondrial respiration, and energy-linked reduction of NAD+. Additionally, hydrogen peroxide production is increased, which may lead to oxidative stress and the formation of reactive oxygen species. 98-72-6

66826

C6H6AsNO5

246.946190 No data.

298 - 300°C

Oral (L2) ; inhalation (L2); dermal (L2)

Arsenic and its metabolites disrupt ATP production through several mechanisms. At the level of the citric acid cycle, arsenic inhibits pyruvate dehydrogenase and by competing with phosphate it uncouples oxidative phosphorylation, thus inhibiting energy-linked reduction of NAD+, mitochondrial respiration, and ATP synthesis. Hydrogen peroxide production is also increased, which might form reactive oxygen species and oxidative stress. Arsenic's carcinogenicity is influenced by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. The binding of other arsenic protein targets may also cause altered DNA repair enzyme activity, altered DNA methylation patterns and cell proliferation. (T1, A17)

Arsenic is absorbed mainly by inhalation or ingestion, as to a lesser extent, dermal exposure. It is then distributed throughout the body, where it is reduced into arsenite if necessary, then methylated into monomethylarsenic (MMA) and dimethylarsenic acid (DMA) by arsenite methyltransferase. Arsenic and its metabolites are primarily excreted in the urine. Arsenic is known to induce the metal-binding protein metallothionein, which decreases the toxic effects of arsenic and other metals by binding them and making them biologically inactive, as well as acting as an antioxidant. (L20) 3, not classifiable as to its carcinogenicity to humans. (L135)

(4-nitrophenyl)arsonic acid is found in animal feed.

Acute Oral: 0.005 mg/kg/day (L134) Chronic Oral: 0.0003 mg/kg/day (L134) Chronic Inhalation: 0.01 mg/m3 (L134)

Hypovolemia from capillary leakage (third-spacing of fluids) is a common, serious, early effect. Muscle cramps, facial edema, bronchitis, dyspnea, chest pain, dehydration, intense thirst, and fluid-electrolyte disturbances are also common following significant exposures. A garlic-like odor of the breath and feces may also occur. After absorption, arsenic may cause multi-organ failure by inhibiting sulfhydryl-containing enzymes. Encephalopathy, with headache, lethargy, mental confusion, hallucinations, emotional lability, memory loss and delirium may occur; seizures, stupor, convulsions, coma, and death may follow within 24 hours of a severe acute exposure. Dysrhythmias (particularly QTc prolongation and torsade de pointes), cardiomyopathy, ARDS, hepatitis, rhabdomyolysis, hemolysis, and renal failure may develop over several days. The sequence of chronic poisoning involves hyperpigmentation, and eczematoid and allergic dermatitis. muscle fasciculations; gross tremors; ataxia; incoordination; and mental confusion. Muscular weakness, limb tenderness and difficulty walking may follow. The final phase consists of peripheral sensory neuropathy of the hands and feet. That may be associated with a motor neuropathy as well (T36).

Initial signs and symptoms of arsenic ingestion include burning lips, throat constriction and dysphagia, followed by excruciating abdominal pain, hemorrhagic gastritis, gastroenteritis, severe nausea, projectile voting, profuse "rice water-like" diarrhea, with hypovolemia that may result in hypotension and an irregular pulse. The sequence of chronic poisoning involves weakness, anorexia, hepatomegaly, jaundice, and gastrointestinal complaints, followed by conjunctivitis, irritation of the throat and respiratory tract. ther effects of chronic exposure include conjunctivitis with irritation and lacrimation; hair, skin and nail changes; hyperkeratosis of feet and hands; and melanosis, with pigment spots in corneal and conjunctival epithelium. Peripheral nervous system symptoms may include numbness, burning, and tingling of the hands and feet; pain; paresthesias; tenderness (T36). Aggressive decontamination with gastric lavage is recommended if the patient has consumed a potentially life-threatening dose and if the patient is not vomiting (T36).

2009-03-06T18:58:30Z

2026-05-14T19:09:38Z

Metallothionein-2 (P02795) Metallothionein-1G (P13640) Metallothionein-1H (P80294) Metallothionein-3 (P25713) Metallothionein-1F (P04733) Metallothionein-1E (P04732) Metallothionein-1X (P80297) Metallothionein-1A (P04731) Metallothionein-1B (P07438) Metallothionein-1M (Q8N339) Metallothionein-4 (P47944) Metallothionein-1L (Q93083) Arsenite methyltransferase (Q9HBK9) (L92)

62629

C015389

(4-Nitrophenyl)arsonic acid

DB11437

true

Arsenite methyltransferase (Q9HBK9) (L92)

O[As](O)(=O)C1=CC=C(C=C1)N(=O)=O

C6H6AsNO5

InChI=1S/C6H6AsNO5/c9-7(10,11)5-1-3-6(4-2-5)8(12)13/h1-4H,(H2,9,10,11)

FUUFQLXAIUOWML-UHFFFAOYSA-N

247.0371

246.946193724

Exogenous Solid 0.88

HMDB31822

CHEMBL1721359

60190

CHEM000264

NS00078889

(4-nitrophenyl)arsonic acid

103.35

39.3711

17.225833391286972

3.19594099098468

-1

0.06

-1.81

3.83e+00 g/l

Organic compounds Benzenoids Benzene and substituted derivatives Nitrobenzenes

CED0019165

FUUFQLXAIUOWML-UHFFFAOYSA-N

40000000000000001000000000000000000000000000000000000000000000000000000004024000000080000001000000000400040000000010000000200000000000000000000000000000000000000000000000000001000000000000000000001000000000000001000000000000000000020000000000000000000000000080000000000000000000000000000000000000000000000000000000000000000000000000000000000040000000200000000000000420000000000000040000000000000000000001000000000000000000000

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

776t3gAAAAAQAAAAAwAAAAAAAAANAAAADQAAAIABCABgAAAAAQEhICAAAAAF CABgAAAAAQEIACgAAAADAgZAKAAAAAMEBkBoAAAAAwMBBkBoAAAAAwMBBkAo AAAAAwQGQGgAAAADAwEGQGgAAAADAwEHACoAAAABAwQIACoAAAD/AwEIACgA AAADAgsAAQABAgABAwgCAQQABAVoDAUGaAwGB2gMBwhoDAgJaAwHCiAKCyAK DCgCCQRoDEIBAAAABgQJCAcGBRcEAAAAAAAAABY=

2026-09-19T03:59:37Z